TY - JOUR
T1 - Activation of inflammation and coagulation after infusion of C-reactive protein in humans
AU - Bisoendial, Radjesh J.
AU - Kastelein, John J. P.
AU - Levels, Johannes H. M.
AU - Zwaginga, Jaap J.
AU - van den Bogaard, Bas
AU - Reitsma, Pieter H.
AU - Meijers, Joost C. M.
AU - Hartman, Daniel
AU - Levi, Marcel
AU - Stroes, Erik S. G.
PY - 2005
Y1 - 2005
N2 - C-reactive protein (CRP) has been postulated to play a causal part in atherosclerosis and its acute complications. We assessed the effects of CRP-infusion on coagulation and inflammatory pathways to determine its role in atherothrombotic disease. Seven male volunteers received an infusion on two occasions, containing 1.25 mg/kg recombinant human CRP (rhCRP) or diluent, respectively. CRP-concentrations rose after rhCRP-infusion from 1.9 (0.3 to 8.5) to 23.9 (20.5 to 28.1) mg/L, and subsequently both inflammation and coagulation were activated. This sequence of events suggests that CRP is not only a well known marker of cardiovascular disease, but is also probably a mediator of atherothrombotic disease
AB - C-reactive protein (CRP) has been postulated to play a causal part in atherosclerosis and its acute complications. We assessed the effects of CRP-infusion on coagulation and inflammatory pathways to determine its role in atherothrombotic disease. Seven male volunteers received an infusion on two occasions, containing 1.25 mg/kg recombinant human CRP (rhCRP) or diluent, respectively. CRP-concentrations rose after rhCRP-infusion from 1.9 (0.3 to 8.5) to 23.9 (20.5 to 28.1) mg/L, and subsequently both inflammation and coagulation were activated. This sequence of events suggests that CRP is not only a well known marker of cardiovascular disease, but is also probably a mediator of atherothrombotic disease
U2 - https://doi.org/10.1161/01.RES.0000163015.67711.AB
DO - https://doi.org/10.1161/01.RES.0000163015.67711.AB
M3 - Article
C2 - 15774855
SN - 0009-7330
VL - 96
SP - 714
EP - 716
JO - Circulation Research
JF - Circulation Research
IS - 7
ER -